Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Proteostasis Therapeutics Inc    PTI

PROTEOSTASIS THERAPEUTICS INC

(PTI)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Proteostasis Therapeutics Up 25%; BlackRock Disclosed 5.9% Stake Friday

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 03:07pm EST

By Josh Beckerman

Shares of biopharmaceutical company Proteostasis Therapeutics recently traded up 25.2% to $4.02.

Late Friday, BlackRock disclosed a 5.9% stake in Proteostasis.

In December, Proteostasis announced a licensing agreement with Roche Holding Genentech unit.

Write to Josh Beckerman at josh.beckerman@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BLACKROCK INC 2.02% 431.95 Delayed Quote.7.78%
PROTEOSTASIS THERAPEUTICS INC -1.69% 4.07 Delayed Quote.25.62%
ROCHE HOLDING LTD. 0.68% 272.55 Delayed Quote.11.98%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROTEOSTASIS THERAPEUTICS
02/11PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (for..
AQ
02/11Proteostasis Therapeutics Up 25%; BlackRock Disclosed 5.9% Stake Friday
DJ
02/06PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (for..
AQ
02/06PROTEOSTASIS THERAPEUTICS : Appoints Emmanuel Dulac and Kim Drapkin to Board of ..
PR
01/07PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Reg..
AQ
2018PROTEOSTASIS THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2018PROTEOSTASIS THERAPEUTICS : Provides Clinical Enrollment Update
PR
2018Proteostasis in Licensing Pact With Roche's Genentech
DJ
2018PROTEOSTASIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Re..
AQ
2018PROTEOSTASIS THERAPEUTICS : Announces Global License Agreement with Genentech
PR
More news
Financials ($)
Sales 2018 3,95 M
EBIT 2018 -65,4 M
Net income 2018 -63,5 M
Finance 2018 103 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 24,5x
EV / Sales 2019 42,0x
Capitalization 200 M
Chart PROTEOSTASIS THERAPEUTICS INC
Duration : Period :
Proteostasis Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTEOSTASIS THERAPEUTICS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 13,8 $
Spread / Average Target 239%
EPS Revisions
Managers
NameTitle
Meenu Chhabra Karson President, Chief Executive Officer & Director
Michael James Barrett Chairman
Marija Zecevic Chief Operating Officer
Helen M. Boudreau Treasurer, Chief Financial & Accounting Officer
Po-Shun Lee Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOSTASIS THERAPEUTICS INC25.62%200
GILEAD SCIENCES6.11%87 436
VERTEX PHARMACEUTICALS12.08%48 081
REGENERON PHARMACEUTICALS9.37%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252